Monitoring Deferiprone Therapy
Patients on deferiprone require weekly absolute neutrophil count (ANC) monitoring for the first 6 months, then every 2 weeks for months 6-12, followed by every 2-4 weeks thereafter, with immediate discontinuation if ANC falls below 1.5 × 10⁹/L. 1
CBC with Differential and ANC Monitoring Schedule
The FDA-mandated monitoring protocol is structured in three phases based on treatment duration:
- Months 0-6: Weekly ANC monitoring
- Months 6-12: ANC every 2 weeks
- After 12 months: ANC every 2-4 weeks (or at transfusion intervals if no prior ANC interruptions)
This tiered approach reflects the highest risk period early in therapy, with the option to reduce frequency in stable patients 1.
Critical ANC Thresholds and Actions
For neutropenia (ANC 0.5-1.5 × 10⁹/L):
- Immediately discontinue deferiprone
- Stop all other medications that may cause neutropenia
- Obtain daily CBC with differential until ANC recovers to ≥1.5 × 10⁹/L
- Do not rechallenge unless benefits clearly outweigh risks 1
For agranulocytosis (ANC <0.5 × 10⁹/L):
- Immediately discontinue deferiprone permanently
- Consider hospitalization
- Daily CBC monitoring until recovery
- Do not resume deferiprone unless potential benefits substantially outweigh risks 1
The American Heart Association consensus reinforces weekly ANC monitoring to detect early agranulocytosis, noting that agranulocytosis occurs in approximately 1% of patients (0.6 cases per 100 patient-years) 2.
Additional Laboratory Monitoring
Monthly monitoring:
- ALT levels (7.5% of patients develop elevations; interrupt therapy if persistent increases occur) 1
Every 2-3 months:
- Serum ferritin to assess efficacy (consider interrupting if consistently <500 mcg/L) 1
Annually:
- Plasma zinc levels (supplement if deficient) 1
Patient Education Requirements
Instruct patients to:
- Immediately stop deferiprone and contact their physician for any signs of infection (fever, sore throat, flu-like symptoms)
- Report these symptoms even between scheduled monitoring visits
- Understand that agranulocytosis can be fatal if not detected early 1
Important Clinical Caveats
Regarding continuation during mild neutropenia: While some research suggests that mild, transient neutropenia may not always progress to agranulocytosis 3, 4, and real-world data shows less frequent monitoring doesn't necessarily increase risk 4, the FDA label takes precedence and mandates immediate discontinuation at ANC <1.5 × 10⁹/L 1. The 1.7% agranulocytosis rate in clinical trials and reports of fatal outcomes justify this conservative approach 1.
Risk stratification: Recent data indicates serious infection risk increases substantially when ANC drops below 0.2 × 10⁹/L (13.2% serious infection rate vs 7.7% at 0.2-0.5 × 10⁹/L) 5. This underscores the importance of early detection through frequent monitoring.
Monitoring frequency reduction: Individual reduction in monitoring frequency may be considered after 12 months based on the healthcare provider's assessment of patient reliability and understanding of risk minimization measures 1. However, this requires careful patient selection and should not be routine practice.